Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relmacabtagene autoleucel versus standard second-line therapy in adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
CTR20221579Phase 3Active
- Sponsor
- WuXi AppTec
- Start
- Jul 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of relmacabtagene autoleucel in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 7 more (2 arms), sponsored by WuXi AppTec. Primary endpoint: Event-free survival. Started Jul 2022; status: active.
02
Drugs
relmacabtagene autoleucel
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphomahigh-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH)follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20221579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221579.